Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GERN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Imetelstat FDA approved Jun 2024 · Rytelo |
MDS (Myelodysplastic Syndrome) | Phase 4 · NCT07939451 | Not yet recruiting |
| GRN163L | Breast Cancer | Phase 1 · NCT00732056 | Completed |
| Fludarabine | Recurrent Childhood Acute Myeloid Leukemia | Phase 1 · NCT06247787 | Recruiting |
Also used in these trials (approved or third-party drugs, not GERN's own candidates): Paclitaxel, Bevacizumab, Azacitidine, Hydrocortisone Sodium Succinate, Trastuzumab, Cytarabine, Leucovorin Calcium, Methotrexate, Ruxolitinib, Venetoclax.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GERN holds $337.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 364.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GERN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 66,502,728 | 10.32% | 2026-06-30 |
| Soleus Capital Master Fund, L.P. | Institution (13G, 5%+) | 41,508,659 | 6.44% | 2026-03-31 |
| Robert J. Spiegel Director · +400,000 options |
Insider | 212,161 | 0.03% | 2026-09-30 |
| John A Scarlett Chairman, President and CEO, Director · +2.87M options |
Insider | 137,500 | 0.02% | 2025-02-27 |
| James Ziegler EVP, Chief Commercial Officer |
Insider | 100,000 | 0.02% | 2025-02-27 |
| Harout Semerjian President & CEO, Director · +4.00M options |
Insider | 53,500 | 0.01% | 2026-11-13 |
| Scott Alan Samuels EVP, Chief Legal Officer · +725,000 options |
Insider | 26,682 | 0.00% | 2025-02-27 |
| Michelle Robertson EVP, CHIEF FINANCIAL OFFICER · +1.74M options |
Insider | 17,645 | 0.00% | 2026-02-17 |
| V Bryan Lawlis Director · +180,000 options |
Insider | 13,300 | 0.00% | 2025-05-09 |
| Timothy Williams EVP and Chief Legal Officer · +2.50M options |
Insider | 12,000 | 0.00% | 2026-11-16 |
| Ahmed ElNawawi EVP, Chief Commercial Officer · +3.00M options |
Insider | 10,000 | 0.00% | 2025-10-20 |
Share count 644,238,859 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GERN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →